Therapy News and Research

RSS

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

2 Apr 2012

Hypoxia in tumors can predict prostate cancer recurrence in men

Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy.

2 Apr 2012

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012.

2 Apr 2012

$Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer$

Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer

The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.

2 Apr 2012

Autism more common than previously thought

Just last week, U.S. health authorities announced that autism is more common than previously thought. About 1 in 88 children in the United States have an autism spectrum disorder, according to the report. Autism spectrum disorders are developmental conditions associated with impaired social communication and repetitive behaviors or fixated interests. Diagnoses have risen 78% since 2000, partly because of greater awareness, and partly for reasons entirely unknown. Most medications don't help, and while some find improvements with intense (and expensive) behavioral therapy, there is no cure.

1 Apr 2012

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Researchers found a treatment that was much more effective in removing fat from arteries than established methods. The vaccine can be given as an injection or in a slightly different form as a nasal spray. A trial on 144 heart disease sufferers is under way in the US and Canada.

1 Apr 2012

Hormones use and breast cancer risk

...

1 Apr 2012

Autism rate soars to 1 in 88 children

The number of children with autism in America has climbed 23 percent in the last two years, but the increase could be partially attributable to better diagnoses, officials say.

31 Mar 2012

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA).

31 Mar 2012

Epilepsy community welcomes IOM's new landmark study report

Responding to today's release of the Institute of Medicine 's (IOM) new report on the public health dimensions of the epilepsies, a cooperative group of professional and consumer organizations with special interest in epilepsy has issued the following joint statement.

31 Mar 2012

ASI to present innovative technology solutions at ASA's Aging in America conference

Anthurium Solutions, Inc. (ASI), a technology and solutions company offering turnkey and custom in-the-cloud solutions that enable new health care delivery models, will present during the American Society on Aging (ASA)'s Aging in America, the largest multidisciplinary aging conference in the country.

31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo.

31 Mar 2012

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Accuray Incorporated, the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

IMS supports new guidance on glucocorticoid use

The International Osteoporosis Foundation, along with the European Society for Calcified Tissue, launched new guidance on glucocorticoid use at the European Congress on Osteoporosis and Osteoarthritis (which took place in Bordeaux from March 21 - 24, 2012). Given the special relevance to postmenopausal women, the International Menopause Society (IMS) is supporting the publication of the guidance.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

SAP protein promotes deposition of amyloid beta in Alzheimer's

The deposition of amyloid beta in the brain of individuals with Alzheimer's disease is the focus of much research into both its cause and treatment.

31 Mar 2012

Therapy News and Research

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Hypoxia in tumors can predict prostate cancer recurrence in men

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer

Autism more common than previously thought

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Hormones use and breast cancer risk

Autism rate soars to 1 in 88 children

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

Epilepsy community welcomes IOM's new landmark study report

ASI to present innovative technology solutions at ASA's Aging in America conference

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Abbott receives CE Marking for PLEX-ID instrument and assays

IMS supports new guidance on glucocorticoid use

Bionovo 2011 total revenues decrease to $0.3 million

SAP protein promotes deposition of amyloid beta in Alzheimer's

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News